Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.

Stanislav LazarevMarcher R ThompsonNelson N Stone Richard G Stock

Published in: BJU international (2018)

LDR-BT yields excellent survival rates, with a 17-year PCSS rate of 97%. In all, 18% of patients with biochemical relapse failed at >10 years after implantation, which justifies their continued follow-up.

Keyphrases

prostate cancer
low dose
high dose
free survival
radical prostatectomy
radiation therapy
type diabetes
skeletal muscle